A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens. (March 2015)

• Record Type: Journal Article
• Authors: Broglio, Kristine R; Daar, Eric S; Quintana, Melanie; Yuan, Yong; Kalsekar, Anupama; Spellberg, Brad; Lewis, Roger J; Akker, Dan Van Den; Detry, Michelle A; Le, Trong; Berry, Scott M
• Is Part Of: Journal of comparative effectiveness research. Volume 4:Number 2(2015)
• Page Start: 101
• Page End: 114
• Publication Date: 2015-03
• Subjects: Bayesian hierarchical model -- boceprevir -- comparative effectiveness -- hepatitis C -- meta-analysis -- sustained virologic response -- telaprevir; Medical care -- Research -- Periodicals; Medical care -- Research -- Evaluation -- Periodicals; Medical care -- Decision making -- Periodicals; Evidence-based medicine -- Periodicals; Medicine, Comparative -- Periodicals; 362.1072
• DOI: 10.2217/cer.14.69
• Languages: English
• ISSNs: 2042-6305

Abstract

Aim: Many hepatitis C virus regimens are unlikely to be compared head to head. In more difficult to treat populations where there is no standard of care, trials are single arm. We describe a flexible meta-analysis platform in this setting.Methods: Our meta-analysis is literature based. We illustrate our methodology and show how inference can be extended to single-arm trials.Results: As an example, in the single arm setting, a regimen with response rates of 84, 72 and 54% in genotype 1a across treatment naive, previous partial responders and previous null responders, respectively, would have 95% probability of superiority to IFN-α + RBV + TPV.Conclusion: This is a rigorous approach to comparative effectiveness that accounts for varying patient populations and plans for the incorporation of emerging treatments.